KRTX News and Press, Karuna Therapeutics Inc. From 03/18/21

The following slide deck was published by Karuna Therapeutics, Inc. in conjunction with this event. For further details see: Karuna Therapeutics (KRTX) Presents At 10th Annual SVB Leerink Global Healthcare Conference

With an estimated ~$530B war chest in total, large biopharma companies will continue to drive M&A activity in 2021, the analysts at Goldman Sachs predicted in a new analysis of the sector.Noting a ~110% YoY rise in deal volumes in February including ~221% YoY growth in U.S. mid-cap deals,...

Karuna Therapeutics (KRTX) has priced its public offering of ~2.08M common shares at $120.00/share, for expected gross proceeds of ~$250M.Underwriters' over-allotment is an additional 312.5K shares.Closing date is March 4.Previously (March 1): Karuna Therapeutics to raise capital in proposed ...

Karuna Therapeutics, Inc. (NASDAQ: KRTX) (“Karuna”), a clinical-stage biopharmaceutical company driven to create and deliver transformative medicines for people living with psychiatric and neurological conditions, today announced the pricing of an underwritten public offer...

Karuna Therapeutics (KRTX) announces that it has commenced an underwritten public offering of $200M shares.It expects to grant the underwriters a 30-day option to purchase up to an additional $30M of shares.All the shares in the proposed offering are to be sold by Karuna.Goldman Sac...

Karuna Therapeutics (KRTX): Q4 GAAP EPS of -$0.89 beats by $0.03.Cash, cash equivalents and available-for-sale investments of $322.33M.CEO comment :“Looking ahead, 2021 is expected to be a year of execution and expansion for Karuna, as we anticipate having comprehensive registrati...

Two Phase 3 trials, EMERGENT-2 and EMERGENT-4, initiated evaluating KarXT for the treatment of psychosis in adults with schizophrenia Results from the Phase 2 EMERGENT-1 clinical trial of KarXT in schizophrenia published in the New England Journal of Medicine First two...

KarXT demonstrated statistically significant and clinically meaningful improvements in primary and key secondary efficacy measures compared with placebo Incidences of somnolence, weight gain and extrapyramidal symptoms were similar in KarXT and placebo treatment groups ...

PureTech Health plc (LSE: PRTC, Nasdaq: PRTC) (“PureTech” or the “Company”), a clinical-stage biotherapeutics company dedicated to discovering, developing and commercializing highly differentiated medicines for devastating diseases, announced that it has sold 1 m...

Karuna Therapeutics (KRTX) has ended the three-day winning streak to lose ~5.6% so far today despite the outperform rating initiated by RBC Capital Markets with a price target of $160.00 per share, ~27.5% upside to the previous close.The analyst Brian Abrahams and the team note the ...